



## UCB's Executive Committee welcomes a new member

- **Pascale Richetta** to join the Biopharma company as head of the Bone therapy Patient Value Unit as from February 1, 2016.

**Brussels (Belgium), January 15, 2016 – 7:00 CET** – UCB announces today that Pascale Richetta is joining the company as Executive Vice President, member of the Executive Committee and reporting to CEO Jean-Christophe Tellier. Pascale Richetta will head the Bone Patient Value Unit of UCB. The position was created last year as part of the company's new Patient Value Organization. It had been filled ad interim by Iris Loew Friedrich who had taken on that extra role in addition to her responsibilities as Chief Medical Officer and Head of the Development and Medical Practices.

Pascale Richetta, a Medical Doctor, has had a long and successful career in the pharmaceutical sector. She possesses over 20 years of commercial experience managing traditional pharmaceuticals and complex biologics. She joins UCB from Abbvie where she was Vice President, Western Europe and Canada. Prior to this she held several management positions at Abbott, GSK, Ipsen and Servier, successfully launching these companies' key drugs on several international markets.

Jean-Christophe Tellier, UCB's CEO, said: "We are very happy to welcome Pascale on our team to lead our Bone Patient Value Unit and take our investigational osteoporosis drug *romosozumab* through its next development steps. We would also like to thank Iris Loew-Friedrich for taking on that role ad interim for the last year in addition to her other broad responsibilities. *Romosozumab*, which we develop in partnership with Amgen is progressing as planned with key milestones expected in the course of 2016."

### For further information

#### Corporate Communications

France Nivelles,  
Global Communications, UCB  
T +32.2.559.9178, [france.nivelles@ucb.com](mailto:france.nivelles@ucb.com)

Laurent Schots,  
Media Relations, UCB  
T+32.2.559.92.64, [laurent.schots@ucb.com](mailto:laurent.schots@ucb.com)

#### Investor Relations

Antje Witte,  
Investor Relations, UCB  
T +32.2.559.94.14, [antje.witte@ucb.com](mailto:antje.witte@ucb.com)

Isabelle Ghellynck,  
Investor Relations UCB  
T +32 2 559 9588, [isabelle.ghellynck@ucb.com](mailto:isabelle.ghellynck@ucb.com)

**About UCB**

UCB, Brussels, Belgium ([www.ucb.com](http://www.ucb.com)) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8000 people in approximately 40 countries, the company generated revenue of €3.3 billion in 2014. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB\_news

**Forward looking statements**

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees.

Additionally, information contained in this document shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction. UCB is providing this information as of the date of this presentation and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.

There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.

Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.